Skip to content

Vesugen

Synthetic tripeptide vascular bioregulator. Promotes endothelial cell renewal, improves vascular function, supports cardiovascular health. Sequence: Lys-Glu-Asp.

Intelligence Profile

Research Papers

The research on Vesugen (peptide KED) consists primarily of laboratory studies examining its effects on cellular aging and neurological function. No clinical trials in humans were identified in the available literature.

Cellular Aging and Stem Cell Research

Several laboratory studies have investigated Vesugen's effects on cellular aging processes. A 2020 study published in Molecular Biology Reports examined gene expression in aging human mesenchymal stem cell cultures and found that short peptides, including Vesugen, appeared to modulate cellular aging markers (PMID: 32399807). However, specific sample sizes and detailed methodology were not provided in the available abstracts.

A 2016 study in the Bulletin of Experimental Biology and Medicine investigated peptide regulation of skin fibroblast functions during in vitro aging, suggesting potential anti-aging effects at the cellular level (PMID: 27259496).

Neurological Applications

Research has explored Vesugen's potential neurological applications. A 2021 study published in the Bulletin of Experimental Biology and Medicine examined molecular-genetic aspects of neurogenesis regulation in Alzheimer's disease, focusing on peptide KED (PMID: 34173097).

A 2019 study in the International Journal of Immunopathology and Pharmacology investigated the effect of short peptides on neuronal differentiation of stem cells (PMID: 30791821). Most recently, a 2024 study in the International Journal of Molecular Sciences examined how short peptides protect fibroblast-derived induced neurons from age-related changes (PMID: 39518916).

Cardiovascular Research

Limited research has examined Vesugen's potential cardiovascular applications. A 2016 study published in Advances in Gerontology analyzed molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis (PMID: 28539025).

Research Limitations

The available evidence consists entirely of preclinical laboratory studies, with no human clinical trials identified. Most studies appear to be basic research examining cellular mechanisms, and detailed methodological information including sample sizes is limited in the available abstracts. The research is primarily published in specialized journals focused on aging and molecular biology.

Disclaimer: This information is for research purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.